Data key to boosting trial diversity--and its time for CROs to act, says Phesi

Regulator efforts to boost trial diversity are not enough, according to Phesi. [ABSTRACT FROM AUTHOR]Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)